JP4927530B2 - エポシロン誘導体および照射による増殖性疾患の処置 - Google Patents
エポシロン誘導体および照射による増殖性疾患の処置 Download PDFInfo
- Publication number
- JP4927530B2 JP4927530B2 JP2006504672A JP2006504672A JP4927530B2 JP 4927530 B2 JP4927530 B2 JP 4927530B2 JP 2006504672 A JP2006504672 A JP 2006504672A JP 2006504672 A JP2006504672 A JP 2006504672A JP 4927530 B2 JP4927530 B2 JP 4927530B2
- Authority
- JP
- Japan
- Prior art keywords
- epothilone
- combination
- ionizing radiation
- treatment
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Radiation-Therapy Devices (AREA)
Description
のエポシロン誘導体と、所望により少なくとも1個の薬学的に許容される担体を;電離放射線と組み合わせて投与することを含む、方法を提供する。
上記および下記で、有機基または有機化合物と合わせて言及される“低級”なる用語は、最大7個(7個を含む)、好ましくは最大4個(4個を含む)の炭素原子を有する、分枝または非分枝であってよい化合物または基を各々意味する。
a)電離放射線の前もっての、同時のまたは連続した投与なしでの式Iのエポシロン誘導体の投与(ここで、該投与は連続的、断続的または散発的であってよい);
b)式Iのエポシロン誘導体の、前もっての、同時のまたは連続した投与なしでの電離放射線の投与(ここで、該投与は連続的、断続的または散発的であってよい):
では得られない、相乗的な抗増殖性効果および/またはクローン的(clonogenic)細胞殺傷効果が得られるように、投与することを意味する。
好ましくは、エポシロン誘導体医薬組成物は、経口投与に適する。
腫瘍細胞増殖を、代謝物活性の検出に基づく、比色分析のMTT−様alamarBlueアッセイにより評価した。クローン的生存を決定するために、培養した単一細胞の数を、約100コロニー/皿が、決められた処置で得られるように調節した。24時間異なる薬剤に暴露した後、細胞を照射し、8から10日間増殖させ、その後メタノール/酢酸(75%/25%)に固定し、クリスタル・バイオレットで染色した。50細胞/コロニー以上のコロニーのみを計数した。非処置細胞の平板効率(PE)を決定し、PE(%)=(記録したコロニー/播いた細胞数)×100として計算した。決められた処置での生存フラクション(SF)は、SF=(記録したコロニー)/(播いた細胞数×PE/100)により決定した。クローン的アッセイを少なくとも2回行い、エラーバーが無いのは、極小の標準偏差によるものである。細胞培養の照射は、室温で細胞培養皿(100×100mm)または96ウェルプレート中、Pantak Therapax 3,300kV X線ユニットを使用して、0.7Gy/分で行った。線量測定は、Vigilant−線量計で制御した。
Claims (6)
- 電離放射線と組み合わせて使用するための増殖性疾患の処置用医薬であり、エポシロンBを含む、医薬。
- 増殖性疾患を有する温血動物に投与するための請求項1に記載の医薬であり、エポシロンBが増殖性疾患に対して電離放射線との併用で治療的に有効な量で含まれている、医薬。
- 少なくとも1種の薬学的に許容される担体をさらに含む、請求項1または2に記載の医薬。
- 処置が増殖性疾患の進行の遅延である、請求項1、2または3のいずれかに記載の医薬。
- 増殖性疾患が固形腫瘍である、請求項1、2、3または4のいずれかに記載の医薬。
- 増殖性疾患の処置用の、電離放射線と組み合わせて使用するための医薬の製造のための、エポシロンBの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0305928.4A GB0305928D0 (en) | 2003-03-14 | 2003-03-14 | Organic compounds |
GB0305928.4 | 2003-03-14 | ||
PCT/EP2004/002610 WO2004080458A1 (en) | 2003-03-14 | 2004-03-12 | Treatment of proliferative diseases with epothilone derivatives and radiation |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006520353A JP2006520353A (ja) | 2006-09-07 |
JP2006520353A5 JP2006520353A5 (ja) | 2007-04-19 |
JP4927530B2 true JP4927530B2 (ja) | 2012-05-09 |
Family
ID=9954825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006504672A Expired - Fee Related JP4927530B2 (ja) | 2003-03-14 | 2004-03-12 | エポシロン誘導体および照射による増殖性疾患の処置 |
Country Status (26)
Country | Link |
---|---|
US (2) | US20070129411A1 (ja) |
EP (1) | EP1605937B1 (ja) |
JP (1) | JP4927530B2 (ja) |
KR (1) | KR20050109988A (ja) |
CN (2) | CN101804050A (ja) |
AT (1) | ATE491450T1 (ja) |
AU (1) | AU2004218927A1 (ja) |
BR (1) | BRPI0408366A (ja) |
CA (1) | CA2519037A1 (ja) |
DE (1) | DE602004030545D1 (ja) |
ES (1) | ES2358109T3 (ja) |
GB (1) | GB0305928D0 (ja) |
HK (1) | HK1086493A1 (ja) |
IL (1) | IL170632A (ja) |
IS (1) | IS8059A (ja) |
MA (1) | MA27634A1 (ja) |
MX (1) | MXPA05009808A (ja) |
NO (1) | NO20054723L (ja) |
NZ (1) | NZ542305A (ja) |
PL (1) | PL1605937T3 (ja) |
PT (1) | PT1605937E (ja) |
RU (1) | RU2381799C2 (ja) |
TN (1) | TNSN05226A1 (ja) |
TW (1) | TWI358295B (ja) |
WO (1) | WO2004080458A1 (ja) |
ZA (1) | ZA200506942B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1759115A (zh) | 2002-08-23 | 2006-04-12 | 索隆-基特林癌症研究协会 | 埃坡霉素(epothilone),合成埃坡霉素的中间体,其类似物及其用途 |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP1640004A1 (en) * | 2004-09-24 | 2006-03-29 | Schering Aktiengesellschaft | Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
MX2012013100A (es) | 2010-05-18 | 2013-01-22 | Cerulean Pharma Inc | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001288097A (ja) * | 2000-04-07 | 2001-10-16 | Pg-Txl Co Lp | 水溶性パクリタキセル誘導体 |
WO2002058700A1 (en) * | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
EP0977563B1 (en) * | 1996-12-03 | 2005-10-12 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
ES2384789T3 (es) * | 2001-03-14 | 2012-07-12 | Bristol-Myers Squibb Company | Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas |
-
2003
- 2003-03-14 GB GBGB0305928.4A patent/GB0305928D0/en not_active Ceased
-
2004
- 2004-03-12 CN CN201010145142A patent/CN101804050A/zh active Pending
- 2004-03-12 TW TW093106690A patent/TWI358295B/zh not_active IP Right Cessation
- 2004-03-12 MX MXPA05009808A patent/MXPA05009808A/es active IP Right Grant
- 2004-03-12 BR BRPI0408366-0A patent/BRPI0408366A/pt not_active IP Right Cessation
- 2004-03-12 AT AT04719972T patent/ATE491450T1/de active
- 2004-03-12 CA CA002519037A patent/CA2519037A1/en not_active Abandoned
- 2004-03-12 AU AU2004218927A patent/AU2004218927A1/en not_active Abandoned
- 2004-03-12 NZ NZ542305A patent/NZ542305A/xx not_active IP Right Cessation
- 2004-03-12 RU RU2005131723/14A patent/RU2381799C2/ru not_active IP Right Cessation
- 2004-03-12 ES ES04719972T patent/ES2358109T3/es not_active Expired - Lifetime
- 2004-03-12 CN CNA2004800065814A patent/CN1758908A/zh active Pending
- 2004-03-12 WO PCT/EP2004/002610 patent/WO2004080458A1/en active Application Filing
- 2004-03-12 DE DE602004030545T patent/DE602004030545D1/de not_active Expired - Lifetime
- 2004-03-12 PT PT04719972T patent/PT1605937E/pt unknown
- 2004-03-12 PL PL04719972T patent/PL1605937T3/pl unknown
- 2004-03-12 KR KR1020057017107A patent/KR20050109988A/ko not_active Application Discontinuation
- 2004-03-12 EP EP04719972A patent/EP1605937B1/en not_active Expired - Lifetime
- 2004-03-12 US US10/549,978 patent/US20070129411A1/en not_active Abandoned
- 2004-03-12 JP JP2006504672A patent/JP4927530B2/ja not_active Expired - Fee Related
-
2005
- 2005-08-30 ZA ZA200506942A patent/ZA200506942B/en unknown
- 2005-09-01 IL IL170632A patent/IL170632A/en not_active IP Right Cessation
- 2005-09-13 TN TNP2005000226A patent/TNSN05226A1/en unknown
- 2005-09-23 MA MA28512A patent/MA27634A1/fr unknown
- 2005-10-04 IS IS8059A patent/IS8059A/is unknown
- 2005-10-13 NO NO20054723A patent/NO20054723L/no not_active Application Discontinuation
-
2006
- 2006-06-08 HK HK06106603.0A patent/HK1086493A1/xx not_active IP Right Cessation
-
2011
- 2011-11-08 US US13/291,496 patent/US20120053559A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001288097A (ja) * | 2000-04-07 | 2001-10-16 | Pg-Txl Co Lp | 水溶性パクリタキセル誘導体 |
WO2002058700A1 (en) * | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
JP2005503323A (ja) * | 2001-01-25 | 2005-02-03 | ブリストル−マイヤーズ スクイブ カンパニー | 癌治療のためのエポチロン類似体の投与方法 |
Also Published As
Publication number | Publication date |
---|---|
PL1605937T3 (pl) | 2011-05-31 |
EP1605937B1 (en) | 2010-12-15 |
CN1758908A (zh) | 2006-04-12 |
TWI358295B (en) | 2012-02-21 |
AU2004218927A1 (en) | 2004-09-23 |
JP2006520353A (ja) | 2006-09-07 |
DE602004030545D1 (de) | 2011-01-27 |
US20070129411A1 (en) | 2007-06-07 |
WO2004080458A1 (en) | 2004-09-23 |
NO20054723L (no) | 2005-10-13 |
ATE491450T1 (de) | 2011-01-15 |
NZ542305A (en) | 2009-03-31 |
KR20050109988A (ko) | 2005-11-22 |
ES2358109T3 (es) | 2011-05-05 |
IS8059A (is) | 2005-10-04 |
MXPA05009808A (es) | 2005-10-26 |
ZA200506942B (en) | 2006-07-26 |
US20120053559A1 (en) | 2012-03-01 |
MA27634A1 (fr) | 2005-11-01 |
IL170632A (en) | 2012-01-31 |
RU2005131723A (ru) | 2007-08-20 |
GB0305928D0 (en) | 2003-04-23 |
CA2519037A1 (en) | 2004-03-23 |
EP1605937A1 (en) | 2005-12-21 |
TW200505444A (en) | 2005-02-16 |
CN101804050A (zh) | 2010-08-18 |
TNSN05226A1 (en) | 2007-06-11 |
PT1605937E (pt) | 2011-03-17 |
RU2381799C2 (ru) | 2010-02-20 |
HK1086493A1 (en) | 2006-09-22 |
BRPI0408366A (pt) | 2006-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2804599T3 (en) | COMBINATION THERAPY FOR TREATMENT OF CANCER | |
RU2519750C2 (ru) | Способы лечения множественной миеломы | |
US20210379014A1 (en) | Pharmaceutical compositions and methods | |
BR112019009799A2 (pt) | método para tratar câncer em um paciente | |
US20120053559A1 (en) | Treatment of Proliferative Diseases with Epothilone Derivatives and Radiation | |
RU2313345C2 (ru) | Комбинации, содержащие ингибитор трансдукции сигнала и производное эпотилона | |
KR20220098144A (ko) | 암을 치료하는 데에 사용하기 위한 알파-메틸-dl-티로신의 알킬에스테르 | |
AU2002308218A1 (en) | Combination comprising a signal transduction inhibitor and an epothilone derivative | |
KR20190008557A (ko) | 암의 치료에서의 디히드로테스토스테론 및 디히드로테스토스테론 유도체 및 프로모터 | |
RU2314807C2 (ru) | Комбинированная противоопухолевая терапия, включающая использование замещенных акрилоилпроизводных дистамицина и лучевой терапии | |
AU2008200555B2 (en) | Treatment of proliferative diseases with epothilone derivatives and radiation | |
RU2341260C2 (ru) | Комбинации, включающие производные эпотилона и алкилирующие агенты | |
AU2002366975B2 (en) | Quinazolinone compounds in combined modalities for improved cancer treatment | |
KR20220082862A (ko) | 혈액 악성 종양을 치료하기 위한 병용 요법 | |
KR20190124950A (ko) | Pfi-3를 포함하는 폐암 또는 대장암의 예방 또는 치료용 조성물 | |
CA2516097A1 (en) | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent | |
TW201315461A (zh) | 與放射線治療關聯之包含奧瑞布林(ombrabulin)及西妥昔單抗(cetuximab)之抗腫瘤組合 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070301 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070301 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100824 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110419 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110715 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110725 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111014 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120124 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120209 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150217 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |